Skip to main content

Table 1 The demographic and clinical characteristics of participants

From: Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients

Parameters HC (n = 22) CHB (n = 58) CHC (n = 31)
Age (years) 42 (22–74) 48 (25–76) 54 (34–74)
Gender: Female/male 6/16 17/41 9/22
ALT (U/L) 27 (13–38) 125 (13–2463)* 57 (13–201)*
AST (U/L) 25 (10–36) 106 (21–1932)* 67 (16–173)*
HCV RNA level (Log10 IU/ml) NA NA 6.42 (3.69–8.60)*
HBV DNA level (Log10 IU/ml) NA 7.26 (5.03–9.98)* NA
WBC (×109/L) 5.57 (4.3–9.7) 7.26 (4.60–12.5)* 7.13 (4.8–12.3)*
Lymphocytes (×109/L) 1.70 (1.02–2.7) 2.14 (1.36–3.12) 1.92 (1.45–2.48)
HBsAg (IU/ml) NA 29.63 (2.97–306.68)* NA
HBsAb (mIU/ml) NA 1.12 (0–391.73)* NA
HBeAg (S/CO) NA 2.38 (0.03–540.84)* NA
HBeAb (S/CO) NA 1.36 (0.02–24.57)* NA
HBcAb (S/CO) NA 1.04 (0.03–19.17)* NA
HCVAb (S/CO) NA NA 7.28 (1.09–34.6)*
HBeAg (+/−) NA 36/22 NA
Disease duration (month) NA 100.8 (14.4–324) 12 (7–36)
  1. Data shown are real case number or median (range). Normal values: ALT: <40 IU/L; AST: <40 IU/L, WBC: (4.0-10.0) × 10^9/L, Lin#: (0.8-4.0) × 10^9/L, HBsAg: <0.050 IU/mL, HBsAb: <10.000 mIU/mL, HBeAg: <1.0000 S/CO, HBeAb: <1.000 S/CO, HBcAb: <1.000 S/CO, HCVAb: <1.000 S/CO. HC: healthy control; CHB: Chronic hepatitis B, CHC: Chronic hepatitis C; HBsAg: hepatitis B surface antigen; HBsAb: hepatitis B surface antibody; HBeAg: hepatitis B e antigen; HBeAb: hepatitis B e antibody; HBcAb: hepatitis B core antibody. *P <0. 05 vs. the HC.